Skip to main content
As published for the week of Monday, July 25, 2016

  • Cover Story: Paving the way

    How Amgen, Sandoz IP battles may unleash a flood of Humira, Enbrel biosimilars

    By Steve Usdin, Washington Editor

    Amgen Inc. and the Sandoz unit of Novartis AG are charting a course that could create competitive U.S. markets for two of the biggest prizes in the biosimilars universe, AbbVie Inc.'s Humira adalimumab and Amgen's Enbrel etanercept, which together had U.S. sales of $13.4 billion in 2015.

    Unanimous advisory committee endorsements for ABP 501, Amgen's version of adalimumab, and GP2015, Sandoz's etanercept, suggest the two companies have overcome the formidable scientific and regulatory hurdles to gaining the first FDA approvals for self-injectable biosimilars.

    Full Article

Money Raised in 2016

Last week, the biotech industry raised $21.3 billion, bringing to $40.4 billion the total raised year-to-date. In 2015, a total of $108.8 billion was raised, including $54.8 billion in debt, $29.6 billion in follow-ons, $3.8 billion in PIPEs and other equity, $8.1 billion in IPOs, and $12.6 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial